Goodman WK - Search Results

1

Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder.

Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. Greenberg BD, et al. Among authors: goodman wk. Neuropsychopharmacology. 2006 Nov;31(11):2384-93. doi: 10.1038/sj.npp.1301165. Epub 2006 Jul 19. Neuropsychopharmacology. 2006. PMID: 16855529 Clinical Trial.

2

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.

Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Goodman WK, et al. Arch Gen Psychiatry. 1990 Jun;47(6):577-85. doi: 10.1001/archpsyc.1990.01810180077011. Arch Gen Psychiatry. 1990. PMID: 2112374 Clinical Trial.

3

Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.

DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S. DeVeaugh-Geiss J, et al. Psychopharmacol Bull. 1990;26(1):54-9. Psychopharmacol Bull. 1990. PMID: 2196627 Clinical Trial.

4

Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.

Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA. Chouinard G, et al. Psychopharmacol Bull. 1990;26(3):279-84. Psychopharmacol Bull. 1990. PMID: 2274626 Clinical Trial.

5

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.

Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Goodman WK, et al. Arch Gen Psychiatry. 1989 Jan;46(1):36-44. doi: 10.1001/archpsyc.1989.01810010038006. Arch Gen Psychiatry. 1989. PMID: 2491940 Clinical Trial.

6

Fluvoxamine as an antiobsessional agent.

Goodman WK, Price LH, Rasmussen SA, Heninger GR, Charney DS. Goodman WK, et al. Psychopharmacol Bull. 1989;25(1):31-5. Psychopharmacol Bull. 1989. PMID: 2505302 Review.

7

The Yale-Brown Obsessive Compulsive Scale. II. Validity.

Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. Goodman WK, et al. Arch Gen Psychiatry. 1989 Nov;46(11):1012-6. doi: 10.1001/archpsyc.1989.01810110054008. Arch Gen Psychiatry. 1989. PMID: 2510699

8

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. Goodman WK, et al. Arch Gen Psychiatry. 1989 Nov;46(11):1006-11. doi: 10.1001/archpsyc.1989.01810110048007. Arch Gen Psychiatry. 1989. PMID: 2684084

9

Effects of yohimbine in obsessive compulsive disorder.

Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS. Rasmussen SA, et al. Among authors: goodman wk. Psychopharmacology (Berl). 1987;93(3):308-13. doi: 10.1007/BF00187248. Psychopharmacology (Berl). 1987. PMID: 2829264

10

Treatment of severe obsessive-compulsive disorder with fluvoxamine.

Price LH, Goodman WK, Charney DS, Rasmussen SA, Heninger GR. Price LH, et al. Among authors: goodman wk. Am J Psychiatry. 1987 Aug;144(8):1059-61. doi: 10.1176/ajp.144.8.1059. Am J Psychiatry. 1987. PMID: 3111279 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

379 results

Search Page

Filters